UBS Group
OACC

UBS Group’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

UBS Group’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$759K Sell
71,763
-28,718
-29% -$306K ﹤0.01% 5765
2025
Q4 		$1.06M Buy
100,481
+1,760
+2% +$18.6K ﹤0.01% 5511
2025
Q3 		$1.04M Buy
98,721
+98,711
+987,110% +$1.03M ﹤0.01% 5545
2025
Q2 		$105 Buy
+10
New +$104 ﹤0.01% 9997

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $386M AUM 45.42% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BGIM
Boussard & Gavaudan Investment Management London, United Kingdom $1.06B AUM 4.58% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

UBS Group's OACC Position: Q1 2026 in Review

UBS Group reduced its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 29% in Q1 2026, selling an estimated $306K and leaving 71,763 shares worth $759K. The position accounts for ﹤0.01% of the portfolio, ranked #5765.

UBS Group first reported a position in OACC in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.06M in Q4 2025. 51 funds tracked by Wall St. Rank hold OACC as of Q1 2026.

  • UBS Group held 71,763 shares of Oaktree Acquisition Corp III Life Sciences worth $759K as of Q1 2026.
  • UBS Group sold 28,718 Oaktree Acquisition Corp III Life Sciences shares in Q1 2026, an estimated $306K.
  • Oaktree Acquisition Corp III Life Sciences made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5765 holding.
  • UBS Group first reported a position in Oaktree Acquisition Corp III Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • UBS Group's Oaktree Acquisition Corp III Life Sciences position peaked at $1.06M in Q4 2025.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.